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Abstract 
The tumor-associated antigen EpCAM (epithelial cell-adhesion molecule) (CO17-1A) is 
over expressed by various human carcinomas, including colorectal carcinoma (CRC). This 
antigen can be used as a target structure for specific immunotherapy with vaccines and 
monoclonal antibodies (MAb). Addition of cytokines to MAb therapy may augment immune 
effector functions and chemotherapeutic agents may also add to therapeutic efficacy.  
In this thesis, we have analysed clinical and immunological responses of patients with 
advanced CRC treated with either the murine anti-EpCAM MAb (anti-EpCAM mMAb) or 
its chimeric counterpart (anti-EpCAM cMAb) in combination with cytokines and 
chemotherapeutics. Additionally, sequential analysis of cytokeratin positive (CK+) cells in 
the bone marrow (BM) were made in CRC patients receiving MAb based therapy for 
advanced disease or as adjuvant therapy. 
Pretreatment natural killer (NK) cell cytotoxicity in vitro of peripheral blood 
mononuclear cells was an independent prognostic factor for overall survival and progression 
free survival (PFS) in patients receiving anti-EpCAM MAb based therapy as first-line 
therapy. The results from this study might be used for future patient selection and indicate 
that agents that activate NK cells should be considered to MAb-based treatment regimens.  
The addition of GM-CSF, α-interferon and 5-fluorouracil to anti-EpCAM mMAb seemed 
to improved the antitumor response rate compared to historical control patients treated with 
anti-EpCAM mMAb alone (54% vs 15%) as well as PFS (15 vs 7 weeks). Clinical effects 
were mainly stable disease > 3months (11 of 14 responders) and responding patients 
survived longer than non-responders. The clinical efficacy of anti-EpCAM cMAb and GM-
CSF was not better than in a historical control group who had received the anti-EpCAM 
mMAb and GM-CSF (overall response rates=21% vs 27%, respectively). Anti-idiotypic 
antibody (Ab2) concentrations as well as the frequency of patients mounting an Ab2-
response in anti-EpCAM cMAb treated patients were lower as compared to anti-EpCAM 
mMAb-treated patients (69% vs 100%).  
Following repeated daily subcutaneous (s.c.) injections of exogenous non-glycosylated 
E.coli-derived GM-CSF (molgramostim), the peak serum GM-CSF concentrations declined 
days 5 and 10 as compared to day 1. A dose-dependent increment in total white blood cell 
count was observed, the total numbers of GM-CSF receptor expressing cells increased 
during treatment while a transient decline in expression intensity was observed at day 5. The 
majority of patients developed binding but not neutralizing anti-GM-CSF antibodies. These 
results might support a receptor-mediated clearance of GM-CSF from the circulation. 
Importantly, high dose of GM-CSF resulted in lower antibody-dependent cellular 
cytotoxicity that may reflect immune suppression. Further studies are required to establish 
the optimal biological dose of different cytokines.  
CK+ cells in BM were examined by immunohistochemistry on routinely processed BM 
clots, and CK+ cells were divided into different subtypes; Group A (CK+ probably 
malignant epithelial cells), Group B (CK+ morphologically non-epithelial cells) and Group 
C (CK+ contaminating cells). The presence of Group A cells did not adversely affect the 
prognosis while the presence of Group B cells probably indicates a poor prognosis in 
patients receiving adjuvant therapy. Sequential BM aspirations do not seem to add to the 
existing methods to follow the effect of treatment in CRC.  
These results might provide further clinical studies with MAbs, combined with other 
agents with different modes of action to increase the clinical efficacy of MAb. Ideally, 
patients with a well preserved immune system and low or minimal tumor burden should be 
selected to MAb-based therapy. 
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